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Abstract Adrenaline significantly potentiated late thrombin-
and SFRLLN-induced PtdIns(3,4)P2 production. Furthermore,
the potentiating effect of adrenaline on thrombin-induced
PtdIns(3,4)P2 production was independent on secreted ADP,
whereas, the effect of adrenaline on SFRLLN-induced
PtdIns(3,4)P2 production was completely dependent of secreted
ADP. However, the ADP-dependent accumulation of
PtdIns(3,4)P2 was not required for irreversible platelet aggrega-
tion induced by SFRLLN in the presence of adrenaline. It is
concluded that adrenaline can replace secreted ADP to
potentiate PtdIns(3,4)P2 production in thrombin-stimulated but
not in SFRLLN-stimulated platelets, thus demonstrating a
qualitative difference between platelet stimulation by thrombin
and the thrombin receptor activating peptide SFRLLN. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Most agonists stimulate platelets by intracellular mobiliza-
tion of Ca2 through activation of poly phosphoinositide-spe-
ci¢c phospholipase C (PLC) isozymes, although some agonist
receptors are also coupled to channels facilitating in£ux of
extracellular Ca2 [1]. We have previously demonstrated
that adrenaline powerfully potentiates agonist-induced platelet
aggregation and dense granule secretion in an K2-adrenergic
manner, whereas the catecholamine failed to stimulate these
responses alone; the mechanism underlying the potentiating
e¡ects of adrenaline is not yet known but is regarded to be
upstream of, or including, activation of PLC [2]. Over the last
decade it has, however, become apparent that many agonists
also activate phosphoinositide 3-kinase (PI3K) in platelets, by
mechanisms not involving PLC or mobilization of Ca2, and
that the 3-phosphorylated inositides have many functional
targets in platelets [3].
We have recently demonstrated that the late production of
3-phosphorylated phosphoinositides in thrombin-stimulated
platelets is dependent on synergistic interplay between individ-
ual signal transduction pathways initiated by autocrine ago-
nists (ADP, thromboxane A2, integrin ligation) formed by
activated platelets [4]. Especially, ADP secreted from platelet
dense granules plays a crucial role for thrombin- and
SFRLLN-induced late accumulation of phosphatidylinositol
3,4-bisphosphate (PtdIns(3,4)P2) [4,5]. In view of these results
we explored in this communication if late thrombin- and
SFRLLN-stimulated PtdIns(3,4)P2 production would be po-
tentiated by exogenous added adrenaline. In the present study
we show that adrenaline exerts a strong potentiating e¡ect on
thrombin- and SFRLLN-induced synthesis of PtdIns(3,4)P2
and that this potentiation di¡ers completely between the
two agonists with respect to requirement for secreted ADP.
2. Materials and methods
2.1. Materials
Thrombin was purchased from Parke-Davis, Morris Plains, NJ,
USA. Prof. Nils Olav Solum (Rikshospitalet, Oslo, Norway) gener-
ously provided the synthetic thrombin receptor agonist peptide Ser-
Phe-Arg-Leu-Leu-Asn (SFRLLN). Thrombin and SFRLLN were di-
luted with 0.15 M NaCl to desired concentrations just before the
experiments. Adrenaline was obtained from Nycomed-Pharma, Oslo,
Norway. Sepharose CL-2B was from Pharmacia Biotech, Sweden.
ADP, CP (creatine phosphate), CPK (creatine phosphokinase), the
PI 3-kinase inhibitor wortmannin and LY294002 were supplied by
Sigma, St. Louis, MO, USA. RGDS (Arg-Gly-Asp-Ser, inhibitor of
¢brinogen binding to integrin KIIbL3) was obtained from Calbiochem-
Novabiochem Corporation (San Diego, CA, USA). [32P]Orthophos-
phate ([32P]Pi) was from Amersham International plc, UK.
2.2. Methods
2.2.1. Platelet isolation, labelling and incubation. Platelet-rich plas-
ma (PRP) was prepared from fresh human venous blood anticoagu-
lated with acid citrate dextrose (ACD) obtained at the blood bank,
Haukeland Hospital, Bergen, Norway. To achieve high incorporation
of [32P]Pi in the phosphoinositide experiments, the platelets in PRP
were sedimented by centrifugation at 1200Ug for 10 min and then
suspended in a calcium- and phosphate-free Tyrode’s bu¡er adjusted
to pH 6.7 with ACD before incubation with [32P]Pi (0.5 mCi/ml) for
1 h at 37‡C. The platelets were then transferred by gel ¢ltration into a
calcium- and phosphate-free Tyrode’s bu¡er containing 5 mM glucose
and 0.2% bovine serum albumin at pH 7.3. The concentration of the
gel-¢ltered platelets (GFP), determined by a Coulter Counter, was
adjusted to 3.5U108 cells/ml with the gel ¢ltration solution.
Aggregation of GFP was measured in a chronolog dual channel
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Abbreviations: ACD, acid citrate dextrose; CP, creatine phosphate;
CPK, creatine phosphokinase; GFP, gel-¢ltered platelets; GroPIns,
glycerophosphoinositols; HPLC, high performance liquid chromatog-
raphy; PI3K, phosphoinositide 3-kinase; PtdIns, phosphatidyl-
inositol; PtdIns(3,4)P2, phosphatidylinositol 3,4-bisphosphate;
PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; PtdIns(3,4,5)P3,
phosphatidylinositol 3,4,5-trisphosphate; PRP, platelet-rich plasma;
TLC, thin layer chromatography
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aggregation module interfaced to a PC (Chrono-log Whole Blood-
Lumi ionized calcium aggregometer, Havertown, PA, USA). GFP
was always preincubated 2 min at 37‡C in the absence or presence
of antagonists before stimulation with agonist (thrombin or SFRLLN
and/or adrenaline). Unless otherwise indicated, adrenaline was added
10 s after thrombin or SFRLLN.
2.2.2. Extraction and analysis of 3-phosphorylated glycerophospho-
inositides [4]. In principle, aliquots of platelet incubation mixtures
were mixed with methanol/chloroform/HCl and phase separated. The
organic phase was concentrated and subjected to thin layer chroma-
tography (TLC). The radioactive spots of PtdIns(3,4)P2 and phospha-
tidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) were isolated and
deacylated and ¢nally subjected to gradient high performance liquid
chromatography (HPLC) according to Auger et al [6]. The radioactive
peaks were detected directly in the eluate by Cerenkov scintillation.
The output from the monitor was recorded online with a standard
PC.
2.2.3. Statistics. Results are presented as mean þ S.E.M. The sta-
tistical signi¢cance was determined by paired sample Student’s t-test.
3. Results
3.1. Synergistic stimulatory e¡ect of adrenaline on
thrombin- and SFRLLN-induced synthesis of
PtdIns(3,4)P2
Platelets were stirred with thrombin (0.035 U/ml and
1 U/ml) with or without adrenaline for 5 min before analysis
of radiolabelled phosphoinositides by TLC/HPLC. Adrenaline
by itself (10 Wg/ml) failed to induce late (5 min) production of
PtdIns(3,4)P2 (results not shown). However, as shown in Fig.
1A, when the same concentration of adrenaline was added 10 s
after thrombin (0.035 U/ml), it signi¢cantly enhanced the
thrombin-induced synthesis of PtdIns(3,4)P2. The addition
of wortmannin (100 nM) or LY294002 (25 WM), two unre-
lated inhibitors of PI 3-K, totally abolished thrombin- plus
adrenaline-induced formation of PtdIns(3,4)P2 (data not
shown). The synergistic e¡ect of adrenaline on thrombin-in-
duced production of PtdIns(3,4)P2 seen at 0.035 U/ml was not
observed at a high concentration of thrombin (1 U/ml) (Fig.
1A). In agreement with the results obtained for thrombin
(0.035 U/ml) above, adrenaline enhanced the late (5 min)
SFRLLN-induced accumulation of PtdIns(3,4)P2 at 40 and
100 WM of SFRLLN by 307 þ 97% (S.E.M.) and
422 þ 129%, respectively (Fig. 1B).
3.2. E¡ect of adrenaline on thrombin- and SFRLLN-induced
synthesis of PtdIns(3,4)P2 in the presence of ADP
scavengers and RGDS
As earlier reported [7,8], adrenaline synergistically enhances
thrombin-induced inositol phospholipid metabolism ([32P]PA,
Fig. 1. Thrombin and SFRLLN-induced accumulation of
PtdIns(3,4)P2 is potentiated by adrenaline. Platelets were stirred at
1000 rpm in a two-channel aggregometer for 5 min at 37‡C with
(A) thrombin (0.035 U/ml and 1 U/ml) or adrenaline plus thrombin
together, or with (B) SFRLLN (40 and 100 WM) or adrenaline
(10 Wg/ml) and SFRLLN together. Adrenaline (10 Wg/ml) was added
10 s after stimulation with thrombin or SFRLLN. Radiolabelled de-
acylated glycerophosphoinositols (GroPIns) were analyzed by HPLC
as described in Section 2. A: The data for late (5 min) thrombin-in-
duced PtdIns(3,4)P2 formation are the average of three di¡erent ex-
periments, bars þ S.E.M. P6 0.05 for thrombin (0.035 U/ml)+vehicle
vs. thrombin (0.035 U/ml)+adrenaline. B: The data for late (5 min)
SFRLLN-induced PtdIns(3,4)P2 formation represent averages of
three separate experiments performed in duplicate with 40 WM of
SFRLLN, and two separate experiments performed in duplicate
with 100 WM of SFRLLN, bars þ S.E.M. P6 0.05 for SFRLLN (40
WM)+vehicle vs. SFRLLN (40 WM)+adrenaline.
Table 1
E¡ect of adrenaline on thrombin-induced synthesis of PtdIns(3,4)P2 in the presence of CP/CPK
Agonist PtdIns(3,4)P2 (%)
Vehicle Adrenaline CP/CPK CP/CPK+adrenaline CP/CPK+RGDS CP/CPK+RGDS+
adrenaline
Thrombin (0.035 U/ml) 100 þ 45 267 þ 53a 30 þ 11 189 þ 23b ND ND
Thrombin (1 U/ml) 100 þ 10 96 þ 23 33 þ 15 79 þ 15c 6 þ 3 17 þ 5d
Platelets were preincubated 2 min at 37‡C with or without CP/CPK (5 mM/10 U/ml) and RGDS (150 WM) before activation with thrombin
(0.035 U/ml and 1 U/ml) or adrenaline (10 Wg/ml) plus thrombin together for 5 min as described in Fig. 1. The amount of PtdIns(3,4)P2 forma-
tion in the presence of thrombin alone was set at 100%. The data for late (5 min) PtdIns(3,4)P2 formation are the average of three di¡erent ex-
periments performed in duplicate, mean þ S.E.M.
aP6 0.05 for thrombin (0.035 U/ml)+vehicle vs. thrombin (0.035 U/ml)+adrenaline.
bP6 0.05 for thrombin (0.035 U/ml)+CP/CPK+vehicle vs. thrombin (0.035 U/ml)+CP/CPK+adrenaline.
cP6 0.05 for thrombin (1 U/ml)+CP/CPK+vehicle vs. thrombin (1 U/ml)+CP/CPK+adrenaline.
dP6 0.05 for thrombin (1 U/ml)+CP/CPK+RGDS+vehicle vs. thrombin (1 U/ml)+CP/CPK+RGDS+adrenaline.
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[32P]PIP2 and [32P]PIP) and secretion of ADP+ATP from
dense granules at low concentrations of thrombin. Since se-
creted ADP plays a key role for thrombin- and SFRLLN-
induced late accumulation of PtdIns(3,4)P2 [4,5], we next in-
vestigated whether adrenaline functions as a synergistic poten-
tiator on PtdIns(3,4)P2 synthesis also in the presence of the
ADP scavenger system CP/CPK.
The presence of CP/CPK almost abolished the formation of
PtdIns(3,4)P2 at 0.035 U/ml of thrombin alone, whereas the
synergistic e¡ect of adrenaline on thrombin-induced (0.035
U/ml) PtdIns(3,4)P2 synthesis only was slightly reduced (Table
1 and Fig. 1A). Furthermore, when secreted ADP was re-
moved by CP/CPK we observed synergism between adrenaline
and thrombin on the formation of PtdIns(3,4)P2 also at higher
concentrations of thrombin (1 U/ml) (Table 1), in contrast to
the lack of e¡ect of adrenaline when secreted ADP was al-
lowed to be present (Fig. 1A). The synergistic e¡ect of adren-
aline on thrombin-induced PtdIns(3,4)P2 synthesis was also
found in the presence of both CP/CPK and RGDS which
inhibits ¢brinogen binding to integrin KIIb/L3 (Table 1).
In sharp contrast, the ADP removing enzyme system CP/
CPK eliminated the late (5 min) SFRLLN-induced (100 WM)
production of PtdIns(3,4)P2 both in the presence and absence
of adrenaline (Fig. 2).
Fig. 2. E¡ect of adrenaline on SFRLLN-induced synthesis of
PtdIns(3,4)P2 in the presence of CP/CPK. Platelets were preincu-
bated 2 min at 37‡C with or without CP/CPK before activation
with SFRLLN (100 WM) or adrenaline (10 Wg/ml) and SFRLLN to-
gether. The measurement of SFRLLN-induced PtdIns(3,4)P2 forma-
tion was done after 5 min as described in Fig. 1. The data are rep-
resentative of two separate experiments performed in duplicate,
bars þ S.E.M.
Fig. 3. Inhibition of irreversible aggregation by the PI 3-K inhibitor wortmannin or the ADP-scavenger system CP/CPK is restored by adrena-
line. GFP were stirred at 1000 rpm measured in a chronolog dual channel aggregation module interfaced to a PC. Arrows show additions.
A: SFRLLN (40 WM)+vehicle versus SFRLLN (40 WM)+CP/CPK (5 mM/10 U/ml). B: SFRLLN (40 WM)+vehicle+vehicle versus SFRLLN
(40 WM)+CP/CPK (5 mM/10 U/ml)+adrenaline (10 Wg/ml). C: Platelets were preincubated 2 min at 37‡C with 100 nM wortmannin before acti-
vation with SFRLLN (40 WM)+vehicle or SFRLLN (40 WM)+adrenaline (10 Wg/ml). D: SFRLLN (40 WM)+vehicle+vehicle vs. SFRLLN
(40 WM)+wortmannin (100 nM)+adrenaline (10 Wg/ml).
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3.3. Inhibition of irreversible aggregation by the PI 3-K
inhibitor wortmannin is restored by adrenaline
Fig. 3 shows SFRLLN (40 WM)-induced aggregation in the
presence and absence of CP/CPK (5 mM/10 U/ml), wortman-
nin (100 nM) and adrenaline (10 Wg/ml).
Addition of CP/CPK, which removes secreted ADP, re-
versed SFRLLN-induced platelet aggregation (Fig. 3A), as
previously shown by using the ADPase enzyme apyrase [9].
The addition of adrenaline 90 s after the CP/CPK addition
restored the SFRLLN-induced irreversible aggregation (Fig.
3B).
As shown in Fig. 2, PtdIns(3,4)P2 production in platelets
coactivated with SFRLLN and adrenaline was completely
abolished when platelets were preincubated with CP/CPK.
Thus, potentiation of SFRLLN-induced platelet aggregation
by adrenaline seems to be independent of the 3-phosphorylat-
ed phosphoinositide PtdIns(3,4)P2. Consistent with this hy-
pothesis, Fig. 3C shows that reversion of SFRLLN-induced
irreversible aggregation by the PI 3-K inhibitor wortmannin
(2 min preincubation) was prevented by addition of adrena-
line. As recently reported [5], addition of wortmannin 2 min
after SFRLLN-stimulation reversed platelet aggregation (Fig.
3D). However, addition of adrenaline 2 min after the wort-
mannin addition recovered the SFRLLN-induced platelet ag-
gregation (Fig. 3D).
4. Discussion
In the present study we demonstrated that adrenaline has a
strong synergistic potentiating e¡ect on thrombin- and
SFRLLN-induced synthesis of PtdIns(3,4)P2. The involve-
ment of secreted ADP in this potentiation di¡ered very
much between the two agonists, as the potentiation of
SFRLLN-induced PtdIns(3,4)P2 production was abolished
by the presence of CP/CPK, while for thrombin it was ac-
tually further potentiated by CP/CPK. Particularly, at the
high concentration (1.0 U/ml) of thrombin adrenaline did
not potentiate PtdIns(3,4)P2 production when secreted ADP
was allowed to be present, while adrenaline caused a strong
potentiation when secreted ADP was removed. One plausible
explanation could be that when secreted ADP accumulated
extracellularly, it potentiated PtdIns(3,4)P2 production and
the PtdIns(3,4)P2 production seen was the result of both
thrombin and ADP action on the platelets. When ADP was
removed by CP/CPK, only thrombin’s action alone is mea-
sured which is then potentiated by adrenaline to the same
extent as secreted ADP. The potentiation by adrenaline of
SFRLLN-induced PtdIns(3,4)P2 production obviously de-
pends on secreted ADP in another way than thrombin. Pre-
vious work has showed that SFRLLN-induced platelet acti-
vation is less potent, and acts through di¡erent signalling
pathways, than thrombin-induced platelet activation [9].
Thrombin cleaves the Arg41^Ser42 peptide bond of the G-pro-
tein-coupled, protease-activated receptor PAR1 in human
platelets, thereby releasing a 41 amino acid peptide (TR1ÿ41)
and producing a new amino-terminus starting with the se-
quence SFRLLN that acts as a tethered peptide ligand [10^
12]. Interestingly, TR1ÿ41 is a strong platelet agonist, which is
almost as potent as thrombin [13]. Moreover, studies with
wortmannin indicated that TR1ÿ41-induced downstream sig-
nalling pathways involve PI3K [13]. We found that the syner-
gistic e¡ect of adrenaline on SFRLLN-induced PtdIns(3,4)P2
production was completely dependent on secreted ADP.
Platelets coactivated with ADP and adrenaline did not induce
synthesis of PtdIns(3,4)P2 (data not shown). However, as dis-
cussed above, the potentiating e¡ect of adrenaline on throm-
bin-induced PtdIns(3,4)P2 production seemed to replace the
potentiating e¡ect of secreted ADP. One major di¡erence be-
tween the physiological tethered ligand produced by thrombin
and the added peptide ligand fragment SFRLLN is that
adrenaline can not replace secreted ADP in the case of
SFRLLN, while it seems to replace ADP in the case of throm-
bin. Synergism between adrenaline and thrombin on the for-
mation of PtdIns(3,4)P2 was also found in the presence of
both CP/CPK and RGDS that block ¢brinogen binding to
integrin KIIb/L3 (Table 1). In light of the previous discussion
we therefore speculate that crosstalk between signalling trans-
duction pathways initiated by adrenaline and TR1ÿ41 has a
synergistic stimulatory e¡ect on PI3K in platelets. Further-
more, in preliminary experiments we found that the K2-adren-
ergic antagonist yohimbine totally abolished the potentiating
e¡ect of adrenaline on thrombin-induced PA formation and
PtdIns(3,4)P2 production (data not shown). Thus, the syner-
gistic stimulatory e¡ect of adrenaline on thrombin-induced
PA formation and PtdIns(3,4)P2 production seems to be
transduced through K2-adrenoreceptors.
By using the ADP scavenger CP/CPK- and the PI3K inhib-
itor wortmannin, we con¢rmed previous work [5,9,14] show-
ing that ADP and the PI3K product PtdIns(3,4)P2 are neces-
sary for SFRLLN (PAR1)-induced irreversible platelet
aggregation (Figs. 2 and 3). However, we found further that
addition of adrenaline recovered the CP/CPK- and wortman-
nin-blocked SFRLLN-induced platelet aggregation (Fig. 3).
Thus, ADP signalling and late accumulation of the PI3K
product PtdIns(3,4)P2 is not required for irreversible platelet
aggregation induced by SFRLLN in the presence of adrena-
line, while it is apparently necessary for PtdIns(3,4)P2 produc-
tion. Interestingly, the potentiating e¡ect of adrenaline of ag-
onist-induced platelet aggregation and associated inhibition of
cAMP formation were recently reported to be strongly inhib-
ited or absent in knockout mice which lack the K subunit of
the heterotrimeric G protein Gz (GzK (3/3))[15]. Thus, the
K2-adrenergic downstream e¡ector GzK seems to play a crucial
role in mediating irreversible aggregation in platelets.
In summary, we demonstrate a strong synergistic e¡ect of
adrenaline on thrombin- and SFRLLN-induced PtdIns(3,4)P2
production. The synergism between adrenaline and thrombin
on the accumulation of PtdIns(3,4)P2 is independent on
secreted ADP, whereas the synergistic e¡ect of adrenaline
on SFRLLN-induced PtdIns(3,4)P2 synthesis is entirely de-
pendent on secreted ADP. However, ADP-dependent late
synthesis of PtdIns(3,4)P2 is not required for SFRLLN-in-
duced irreversible platelet aggregation in the presence of
adrenaline.
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